By 2040, there will be
over 700 million people
with diabetes
100% of patients with Type 1 diabetes
>60% of patients with Type 2 diabetes
will develop diabetic retinopathy (DR)
Two patent families with strong claims covering key markets: US, Canada, EU, China, etc.
1st PCT application number: PCT/CA2021050924, July 6th 2021, in national phase
2nd US provisional submitted in Feb 2024 and will be converted to PCT in Aug 2024
In-house & co-development of iRNA-DR1 and iRNA-DR2, in parallel, till the completion of phase I trial
Seeking license partnerships for phase II phase III trials
Development plan and timeline in slides to follow
Devising strategy with reference to existing siRNA therapeutics on the market for other condition
Meeting FDA consultants early and often
Working with local consultants and/or licensees in pursuing key markets regulatory approval, et. EU, China
Diversified funding sources: F&F, grants, non-diluted funding both in Canada and aboard
Milestone based financing: large animal data, IND, phase III, etc.
YEAR
Report of Invention
First US Provisional Filing
First PCT Entering National Phase
Second US Provisional Filing
Winning JDRF Grant
First PCT Filing
Winning Western Innovation Fund
Creation of i-RNA Corporation
IP Transferring from Western
Second PCT Filing
Seed Financing for IND
Series A Financing for Phase I
Second PCT Entering National Phase
Series B Financing for Phase II
Industrial Partnerships
IPO
